Bio Green Med Solution, Inc. (BGMS): Nasdaq/NYSE listing notice — Bio Green Med receives Nasdaq deficiency notice for preferred stock (BGMSP) over minimum MVPHS

Bio Green Med Solution, Inc.

Nasdaq notified that BGMSP's Market Value of Publicly Held Shares fell below $1M for 30 consecutive business days.
Company has 180 days until March 10, 2026 to regain compliance by achieving MVPHS of at least $1M for 10 consecutive days.
Deficiency does not affect common stock (BGMS) listing; preferred stock continues to trade during cure period.
Company will evaluate options if compliance not regained, including potential delisting and Nasdaq appeal process.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5460(a)(2), 5810(c)(3)(D)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5460(a)(2), 5810(c)(3)(D)

Exact text from the filing

September 11, 2025, Bio Green Med Solution, Inc. ( fka Cyclacel Pharmaceuticals, Inc.) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that its 6% Convertible Exchangeable Preferred Stock (listed on the Nasdaq Capital Market under the symbol “BGMSP”) (the “Preferred Stock”) no longer complies with the requirement under Nasdaq Listing Rule 5460(a)(2) to maintain a minimum Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-013703

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.